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Abstract 
Hepatocellular carcinoma (HCC) is a primary malignant liver tumor that commonly occurs 
as a progression of chronic liver inflammation due to long-standing viral hepatitis infection, 
toxins, metabolic conditions, and congenital disorders. In 2018, HCC was the 4​th​ leading 
cause of cancer-related deaths worldwide, accounting for approximately 780,000 deaths in 
total.  
HCC’s prognosis is directly correlated with early detection. Unfortunately, HCC has an 
asymptomatic pattern of growth in the early stages of the disease which makes early 
detection challenging. When HCC progresses to advanced stages, it leaves clinicians with 
limited therapeutic and curative options, leading to high rates of morbidity and mortality. In 
general, one major hurdle in treating advanced cancer is that cancer cells develop drug 
resistance.  
Research studies have elucidated the role of long non-coding RNAs (lncRNAs) in 
progression and drug resistance in various cancers such as bladder cancer, prostate 
cancer, and non-small cell lung cancer. Long non-coding RNAs (lncRNAs) are non-coding 
RNA segments that are >200 nucleotides long that play various roles in biological 
processes regarding DNA, RNA and protein regulation. In carcinogenesis, lncRNAs can 
promote growth and differentiation of cancer stem cell populations, promoting 
chemoresistance and tumor recurrence. The role of lncRNAs in chemoresistance of HCC 
has not been well-studied. There is a need to uncover novel lncRNA biomarkers for both the 
early detection of HCC and to create drug strategies for clinicians when predicting 
chemoresistance.  
The goal of our review is three-fold. Firstly, we aim to describe HCC risk factors, the 
pathologic progression of HCC from benign pathologies such as viral hepatitis and 
non-alcoholic fatty liver disease (NAFLD), current diagnostic standards and challenges, and 
approved treatment options for HCC. Secondly, we aim to explain the molecular role of 
lncRNAs in cancer progression and drug resistance. Lastly, we aim to compile a 
comprehensive list of studied lncRNAs involved in HCC progression and drug resistance, 
their mechanisms of action, their binding partners, and the impact these lncRNAs had on 
metastatic potential and tumor proliferation. Additionally, we aim to include a list of proteins 
involved in HCC and their interactions with lncRNAs.  
